Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
Company Overview
Biogen Idec, Inc. is a global biotechnology company focused on discovering, developing, manufacturing and marketing therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia.
| Name: | Biogen Idec Inc. |
|---|---|
| Address: | 133 Boston Post Road Weston, Massachusetts 02493 |
| Phone: | (781) 464-2000 |
| Email: | jeff.boyle@biogenidec.com |
| Web site: | www.biogenidec.com |
| CEO: | NA |
| % Owned By | Shares Bought In Last 90 Days | Shares Sold In Last 90 Days | |
| Insiders | NA | 110,185 | 80,807 |
| Institutional | 95.21% | NA | NA |
| Change in Short Interest as of 3/15/2013 | -1.15% | ||
| Short Interest as % of Float as of 3/15/2013 | 1.12% | ||
| Number of Employees | 5,950 |
|---|---|
| Revenue per Employee | $921,237 |
| Income per Employee | $231,938 |
| Market Capitalization (thousands) | $45,681,500 |
| Enterprise Value (thousands) | $44,953,047 |
| Auditors Opinion | Unqualified |
Officers and Directors
Bill D Young, George A Scangos, Paul J Clancy, Katherine Dawson, Glenn Pierce, Alfred W Sandrock, Douglas E Williams, Raymond Pawlicki, Theresa Podrebarac, John G Cox, Robert A Licht, Stuart Anthony Kingsley, Steven H Holtzman, Robert W Pangia, Lynn Schenk, Richard C Mulligan, Alexander J Denner, Stephen A Sherwin, Eric K Rowinsky, Caroline D Dorsa, Brian S Posner, Stelios B Papadopoulos, Nancy L Leaming, Gregory F Covino, Kia Khaleghpour
